Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q3 2016 · 10-Q
Revenue$376.70M$376.70M+9.3% vs Q3 2015 Net Income$37.60M$37.60M+2,406.7% vs Q3 2015 EPS Diluted$0.50$0.50+2,400.0% vs Q3 2015 Gross Profit$121,100,000+11.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flowderived$68,400,000−0.6% Free Cash Flowderived$19,700,000−49.6% Margins · derivedGross margin32.1%+0.7 pt vs Q3 2015
Operating margin13.6%+14.6 pt vs Q3 2015
Net margin10.0%+9.5 pt vs Q3 2015
ended Sep 30, 2016 · filed Oct 31, 2016 · 31 d after period end